NCT07893730Not yet recruitingPhase 2
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches (MELODY)
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
MELODY is a prospective, single-arm phase II study introducing routine liquid-biopsy next-generation sequencing for patients with advanced or unresectable breast cancer in Ireland. The study will characterise genomic alterations detected in plasma and tumour tissue, assess concordance and clinical actionability, and evaluate clinical, operational, economic, patient-reported and exploratory translational outcomes.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 13 Oct 2026
- Start date
- 10 Oct 2026
- Primary completion date
- 31 Oct 2028
- Lead sponsor
- University College Cork
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07893730
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 10 Oct 2026 to the primary completion date, 31 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this study intervention are not eligible for this trial.
Other
- Patients who in opinion of supervising clinician are clinically too unwell to participate.
- Pregnant or breastfeeding patients
Who the study is looking for
- Age 18 years or older, male or female
- Locally advanced / inoperable or metastatic breast cancer suitable for systemic therapy, newly diagnosed or previously treated
- Histologically confirmed invasive breast cancer of any subtype
- No limitation on the number of prior lines of therapy
- ECOG Performance Status 0-3
- Capable of providing informed consent and willing to comply with study procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.